Therapeutics for treatment of COVID-19 symptoms
The present disclosure relates to methods of treating Coronavirus-Associated Lung Damage (CALD) and cytokine storm using CALD-treating compounds. The methods can involve administering CALD-treating compounds to a patient suffering from CALD or cytokine storm.
1 . A method of treating COVID-19-associated lung damage (CALD), the method comprising administering to a patient with COVID-19 an effective amount of a pharmaceutical formulation comprising compound II
2 . The method of claim 1 , wherein the patient has a serum concentration of D-dimer greater than 1 μg/ml.
3 . The method of claim 1 , wherein the patient has a serum concentration of interleukin-1β greater than 3 pg/ml.
4 . The method of claim 1 , wherein the patient has a serum concentration of interleukin-6 greater than 7 pg/ml.
5 . The method of claim 1 , wherein the administration results in a decrease of an amount of D-dimer in the patient's blood from greater than 1 μg/ml to less than 1 μg/ml.
6 . A method of treating CALD, the method comprising administering to a patient having an oxygen level of less than 90% as measured by pulse oximetry and a pulmonary compliance of greater than 50 ml/cm H 2 O an effective amount of a pharmaceutical formulation comprising compound II.
7 . The method of claim 6 , wherein the patient has a serum concentration of D-dimer greater than 1 μg/ml.
8 . The method of claim 6 , wherein the patient has a serum concentration of interleukin-1β greater than 3 pg/ml.
9 . The method of claim 6 , wherein the patient has a serum concentration of interleukin-6 greater than 7 pg/ml.
10 . The method of claim 6 , wherein the administration results in a decrease of an amount of D-dimer in the patient's blood from greater than 1 μg/ml to less than 1 μg/ml.
11 . A method of treatment of cytokine storm, the method comprising administering to a patient having a serum level of interleukin-1β greater than 3.2 pg/ml an effective amount of a pharmaceutical formulation comprising compound II.
12 . The method of claim 11 , wherein the patient has a serum concentration of D-dimer greater than 1 μg/ml.
13 . The method of claim 11 , wherein the patient has a serum concentration of interleukin-6 greater than 7 pg/ml.
14 . The method of claim 11 , wherein the administration results in a decrease of an amount of D-dimer in the patient's blood from greater than 1 μg/ml to less than 1 μg/ml.
15 . A method of treatment of cytokine storm, the method comprising administering to a patient having a serum level of interleukin-6 greater than 7 pg/ml an effective amount of a pharmaceutical formulation comprising compound II.
16 . The method of claim 15 , wherein the patient has a serum concentration of D-dimer greater than 1 μg/ml.
17 . The method of claim 15 , wherein the patient has a serum concentration of interleukin-1β greater than 3 pg/ml.
18 . The method of claim 15 , wherein the administration results in a decrease of an amount of D-dimer in the patient's blood from greater than 1 μg/ml to less than 1 μg/ml.
19 . A method of treatment of cytokine storm, the method comprising administering to a patient having a serum level of interleukin-12p70 greater than 40 pg/ml an effective amount of a pharmaceutical formulation comprising compound II.
20 . The method of claim 19 , wherein the patient has a serum concentration of D-dimer greater than 1 μg/ml.
21 . The method of claim 19 , wherein the patient has a serum concentration of interleukin-1β greater than 3 pg/ml.
22 . The method of claim 19 , wherein the patient has a serum concentration of interleukin-6 greater than 7 pg/ml.
23 . The method of claim 19 , wherein the administration results in a decrease of an amount of D-dimer in the patient's blood from greater than 1 μg/ml to less than 1 μg/ml.
24 . A method of treatment of cytokine storm, the method comprising administering to a patient having a serum level of interleukin-23 greater than 15 pg/ml an effective amount of a pharmaceutical formulation comprising compound II.
25 . The method of claim 24 , wherein the patient has a serum concentration of D-dimer greater than 1 μg/ml.
26 . The method of claim 24 , wherein the patient has a serum concentration of interleukin-1β greater than 3 pg/ml.
27 . The method of claim 24 , wherein the patient has a serum concentration of interleukin-6 greater than 7 pg/ml.
28 . The method of claim 24 , wherein the administration results in a decrease of an amount of D-dimer in the patient's blood from greater than 1 μg/ml to less than 1 μg/ml.
29 . A method of treatment of cytokine storm, the method comprising administering to a patient having a serum level of interleukin-27 greater than 1 ng/ml an effective amount of a pharmaceutical formulation comprising compound II.
30 . The method of claim 29 , wherein the patient has a serum concentration of D-dimer greater than 1 μg/ml.
31 . The method of claim 29 , wherein the patient has a serum concentration of interleukin-1β greater than 3 pg/ml.
32 . The method of claim 29 , wherein the patient has a serum concentration of interleukin-6 greater than 7 pg/ml.
33 . The method of claim 29 , wherein the administration results in a decrease of an amount of D-dimer in the patient's blood from greater than 1 μg/ml to less than 1 μg/ml.
34 . A method of treatment of cytokine storm, the method comprising administering to a patient having a D-dimer level of greater than 1 μg/ml an effective amount of a pharmaceutical formulation comprising compound II.
35 . The method of claim 34 , wherein the patient has a serum concentration of interleukin-1β greater than 3 pg/ml.
36 . The method of claim 34 , wherein the patient has a serum concentration of interleukin-6 greater than 7 pg/ml.
37 . The method of claim 34 , wherein the administration results in a decrease of an amount of D-dimer in the patient's blood from greater than 1 μg/ml to less than 1 μg/ml.